Rigel Pharmaceuticals RIGL Estimates

NASDAQ RIGL
$48.75 +0.25 (+0.52%)
As of: Sep 4, 2026 · 11:45 AM EDT
Analyst Estimates

Rigel Pharmaceuticals Inc Revenue Estimates

Periods 27
Next Period Q3 26
Consensus 83.68 M

Analysts expect Rigel Pharmaceuticals Inc to report revenue of 83.68 M for Q3 26, against a range of 75.63 M to 91.73 M. The most recent reported quarter, Q2 26, came in at 78.70 M, a 39.0% beat against the 56.61 M consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 36.84 M55.31 M57.60 M53.33 M101.69 M69.46 M69.80 M58.82 M78.70 M--------
High Estimate 37.09 M45.02 M57.74 M46.03 M90.99 M67.34 M78.67 M67.85 M61.23 M91.73 M86.71 M86.30 M93.29 M104.92 M108.89 M82.56 M116.62 M
Low Estimate 33.29 M41.08 M47.30 M38.47 M80.30 M59.36 M66.93 M60.98 M51.99 M75.63 M74.58 M74.43 M76.81 M86.61 M90.37 M70.27 M108.95 M
Consensus Estimate 35.19 M43.05 M52.52 M42.25 M85.65 M63.35 M72.80 M64.41 M56.61 M83.68 M80.65 M80.36 M85.05 M95.77 M99.63 M76.41 M112.78 M
Analyst Estimates

Rigel Pharmaceuticals Inc Earnings Per Share (EPS) Estimates

Periods 27
Next Period Q3 26
Consensus 1.20

Analysts expect Rigel Pharmaceuticals Inc to report earnings per share of 1.20 for Q3 26, against a range of 1.11 to 1.29. The most recent reported quarter, Q2 26, came in at 0.93, a 832.5% beat against the 0.10 consensus.

Metric Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -0.060.700.800.633.281.4613.540.440.93--------
High Estimate -0.250.060.500.092.910.951.350.790.111.291.350.700.981.473.23-0.400.76
Low Estimate -0.310.060.420.072.450.791.150.730.091.111.130.600.881.212.75-0.480.72
Consensus Estimate -0.280.060.460.082.680.871.250.760.101.201.240.650.931.342.99-0.440.74